(Q35057253)

6 August 2017

1 reference

title

Mitoxantrone in progressive multiple sclerosis: when and how to treat? (English)

1 reference

6 August 2017

0 references

Gonsette RE

1

1 reference

6 August 2017

1 February 2003

1 reference

Journal of the Neurological Sciences

6 August 2017

1 reference

6 August 2017

206

1 reference

6 August 2017

203-208

1 reference

6 August 2017

2

1 reference

Evaluation of mitoxantrone for the treatment of multiple sclerosis

6 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900335-0

Efficacy and toxicity of cyclosporine in chronic progressive multiple sclerosis: a randomized, double-blinded, placebo-controlled clinical trial. The Multiple Sclerosis Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900335-0

Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900335-0

A placebo-controlled, randomized, double-masked, variable dosage, clinical trial of azathioprine with and without methylprednisolone in multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900335-0

Effect of total lymphoid irradiation in chronic progressive multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900335-0

Cyclophosphamide in chronic progressive multiple sclerosis. Maintenance vs nonmaintenance therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900335-0

Morphologic effects of mitoxantrone and a related anthracenedione on lymphoid tissues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900335-0

Immunopharmacologic modulation of experimental allergic encephalomyelitis: low-dose cyclosporin-A treatment causes disease relapse and increased systemic T and B cell-mediated myelin-directed autoimmunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900335-0

Suppression of demyelination by mitoxantrone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900335-0

Suppression of experimental allergic encephalomyelitis by mitoxantrone.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900335-0

Regional suppression, therapy after onset and prevention of relapses in experimental allergic encephalomyelitis by mitoxantrone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900335-0

Suppression of acute and relapsing experimental allergic encephalomyelitis with mitoxantrone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900335-0

[Immunosuppressive therapy of multiple sclerosis with mitoxantrone]

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900335-0

Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900335-0

Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900335-0

Mitoxantrone immunotherapy in multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900335-0

The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900335-0

An open-trial evaluation of mitoxantrone in the treatment of progressive MS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900335-0

Cyclophosphamide in chronic progressive multiple sclerosis: a comparative study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900335-0

Acute promyelocytic leukemia following mitoxantrone as single agent for the treatment of multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900335-0

Secondary leukemias induced by topoisomerase-targeted drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900335-0

A study of therapy-related acute leukaemia after mitoxantrone therapy for multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900335-0

Multiple sclerosis as a cause of atrial fibrillation and electrocardiographic changes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900335-0

Evaluation of myocardial muscle functional parameters in patients with multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900335-0

Abnormalities of cardiac repolarization in multiple sclerosis: relationship with a model of allergic encephalomyelitis in rat

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900335-0

Decrease in heart ventricular ejection fraction during multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900335-0

Cardiac metabolism and function in patients with multiple sclerosis: a combined 31P-MR-spectroscopy and MRI study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900335-0

7 January 2021

Dexrazoxane (ICRF-187).

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900335-0

Doxorubicin reduces the iron(III) complexes of the hydrolysis products of the antioxidant cardioprotective agent dexrazoxane (ICRF-187) and produces hydroxyl radicals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900335-0

The use of serum levels of cardiac troponin T to compare the protective activity of dexrazoxane against doxorubicin- and mitoxantrone-induced cardiotoxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900335-0

In vitro effects of dexrazoxane (Zinecard) and classical acute leukemia therapy: time to consider expanded clinical trials?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900335-0

Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900335-0

Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900335-0

6,9-Bis[(aminoalkyl)amino]benzo[g]isoquinoline-5,10-diones. A novel class of chromophore-modified antitumor anthracene-9,10-diones: synthesis and antitumor evaluations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900335-0

10.1016/S0022-510X(02)00335-0

7 January 2021

Identifiers

DOI

1 reference

release_bi32utfrazelthja3zftlwj26e

6 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/bi32utfrazelthja3zftlwj26e

mapped directly with Wikidata item

24 November 2022

based on heuristic

PubMed ID

12559512

1 reference

PubMed ID

12559512